Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/ac74885b-6bb3-430a-99c5-b9ed455356fe/

BBZA

BB Biotech AG
Chart
55.30 EUR
Latest Week 2026-07-31
HealthcareBiotechnologySMALL
Snapshot 2026-07-26 · 1.0w · Fresh
0.89
OS Score
80.0%
Value
64.0%
Quality
59.0%
Momentum
3/9
F-Score
0.716
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
6 of 23 passing
★
OS Composite
OS 0.890
↗
Trending Value
✗
◆
Quality × Value
QV 0.716
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
Rev +613%
🔄
Shareholder Yield
6.4%
💰
High Yield
Div 7.2%
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
Vol 7%
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
80.0%ile
P/E
2.3×
P/S
2.2×
P/B
0.6×
FCF Yield
0.109
SH Yield
0.064
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
24.00000000
/100 — 1=cheapest
VC2 (Trending Value)
18.00000000
/100
VC3 (Buyback)
17.00000000
/100
P/E of 2.3x places this firmly in deep value territory. FCF yield of 10.9% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
64.0%ile
ROE
0.260
ROA
0.259
Net Margin
0.970
F-Score
3/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
6.131
Earn Growth
6.564
Stability
2.932
lower=better
5yr Consist
No
ROE of 26% is exceptional.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
59.0%ile
6M Return
7.2%
12M Return
7.2%
12-1 Mom
7.2%
Risk-Adj
0.99
Vol 252d
7.3%
Vol 60d
18.6%
↑ Expanding
Max DD 12M
0.0%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (19%) is expanding vs long-term (7%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.89
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 77 peers
Sector Value %ile
89.7%
Sector Quality %ile
48.7%
P/E z-score
-0.69
P/B z-score
-0.67
Sector Avg OS
49.4%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
MED MEDICLIN Aktiengesellschaft 99.0% 97.0% 82.0% 82.0%
DRW8 Drägerwerk AG & Co. KGaA 96.0% 93.0% 58.0% 79.0%
NOV Novo Nordisk A/S 96.0% 98.0% 83.0% 39.0%
M12 M1 Kliniken AG 96.0% 77.0% 92.0% 73.0%
CBHD Coloplast A/S 95.0% 98.0% 92.0% 27.0%
DMP Dermapharm Holding SE 94.0% 71.0% 93.0% 70.0%
DRW3 Drägerwerk AG & Co. KGaA 94.0% 85.0% 58.0% 78.0%
NN6 NanoRepro AG 93.0% 75.0% 70.0% 80.0%
Factor Interactions
Growth at Reasonable Price
Revenue growing 613% with P/E of 2×. Growth isn't fully priced in.
Strong Capital Return
Shareholder yield 6.4% backed by 10.9% FCF yield. Returns are well-funded.
Volatility Expanding
60-day vol (19%) significantly exceeds 252-day (7%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
A
92.1% avg (5 factors)
Quality
A
91.4% avg (3 factors)
Momentum
C
45.2% avg (4 factors)
Risk
A
100.0% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.890—1—
Value %ile0.800—2—
Quality %ile0.640—0—
Momentum %ile0.590—0—
F-Score3.000—8—
Confidence0.667—0—
Volatility0.073—8—
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
2.30
Price / Sales
2.23
Price / Book
0.60
FCF Yield
10.9%
Sales Yield (1/P·S)
0.5040
Shareholder Yield
Div + net buyback / mktcap
6.4%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
26.0%
Return on Assets
25.9%
Net Margin
97.0%
External Financing
Net issuance — lower=better
0.007
MomentumPrice trend strength over different horizons
6M Return
7.2%
12M Return
7.2%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
7.2%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.99
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
613.1%
Earnings Growth (YoY)
656.4%
Earnings Stability (CV)
Lower = more stable
2.932
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
3
Dividend Yield
7.2%
Buyback Yield
-0.8%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
24
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
18
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
17
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity